ResMed shares fell approximately 7% [1] after the respiratory device maker issued a softer-than-expected financial outlook for fiscal 2027 [1], [2].
The decline reflects investor concern over the company's ability to maintain growth amid shifting market conditions and internal sales hurdles. Because ResMed is a leader in sleep apnea and respiratory care, its forecast serves as a bellwether for the broader medical device sector.
The company said the tempered outlook was due to two primary factors: suspended ventilator sales and ongoing macroeconomic uncertainty [1], [2]. These headwinds have led analysts to reconsider the stock's short-term valuation and growth trajectory.
Following the announcement, RBC Capital Markets downgraded the stock to Sector Perform from its previous Outperform rating [3]. The firm also reduced its price target for the company to $234, down from a previous target of $276 [3].
The stock's volatility follows the company's admission that the fiscal 2027 landscape remains challenging. While the company continues to produce essential respiratory equipment, the halt in specific ventilator sales has created a gap in projected revenue streams.
Market analysts are now monitoring whether the macroeconomic uncertainty cited by the company is a temporary dip or a sign of a longer-term contraction in healthcare spending. The seven percent [1] drop in share price indicates a swift reaction from shareholders to the updated guidance.
“ResMed shares fell approximately 7% after the respiratory device maker issued a softer-than-expected financial outlook”
This downturn highlights the vulnerability of specialized medical device manufacturers to sudden regulatory or sales suspensions. By lowering the price target to $234 [3], analysts are signaling that the company's previous valuation was based on growth assumptions that are no longer viable given the current fiscal 2027 projections.
